2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults
As a result, the energy sources that go into fat formation are shifted into an oxidative pathway providing energy for muscle cells
Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study
Conversely, additional diagnoses of hypertension or high cholesterol did not increase GLP-1 initiation rates
Different three-receptor combinations, different metabolic effects, different dosage considerations
Any history of alcohol-related health problems , including liver disease, pancreatitis, gastritis, or previous attempts to reduce drinking Changes in drinking patterns since starting GLP-1 medication, whether increased or decreased consumption, or altered tolerance to alcohol Gastrointestinal symptoms and whether alcohol worsens nausea, vomiting, or other side effects Concerns about alcohol use disorder : If you're finding it difficult to control your drinking, your GP can arrange referral to specialist NHS alcohol services Your GP should provide personalised advice based on your individual circumstances, including other medications, comorbidities, and treatment goals
.png?w=1536&max-h=2752&fit=crop&auto=format)
